Sort   by:  
 Page size 
ProteomicsMultiomics analysis of Papillary thyroid cancers identifies BAIAP2L1-BRAF fusion and requirement of TRIM25, PDE5A and PKCdelta for tumorigenesis
Papillary thyroid carcinoma (PTC) is one of the most common forms of thyroid cancer with a cure rate of over 90% after surgery. However, aggressive forms may still occur, and personalized therapeutic strategies are increasingly required. We subjected patient materials from a cohort of patients whose...
ORGANISM(S): Homo Sapiens (human) 
2023-02-22 | PXD034229 | JPOST Repository
TranscriptomicsExpression data from BRAF-mutant melanoma cell lines
Melanoma cell lines were assessed for differences in gene expression patterns between the lines sensitive and resistant to BRAF and MEK inhibitor drugs. 22 BRAF-mutant melanoma cell lines were assessed for response to BRAF and MEK inhibitors in a 3 day drug treatment dose response assay. Based on t...
ORGANISM(S): Homo sapiens 
2015-08-26 | E-GEOD-45558 | biostudies-arrayexpress
TranscriptomicsOncogenic BRAF regulates oxidative metabolism via PGC1alpha and MITF
We evaluated two matched human cell lines derived from primary melanocytes, termed pmel+BRAF(V600E) and pmel+BRAF(V600E)+MITF. These cells are therefore isogenic with the exception of the expression of MITF. Gene Set Enrichment Analysis of microarray data identified a highly significant induction of...
ORGANISM(S): Homo sapiens 
2013-03-07 | E-GEOD-38007 | biostudies-arrayexpress
TranscriptomicsHuman BRAF-V600E melanoma cell lines drug sensitive vs drug resistant
aCGH of human melanoma cell lines comparing parental (drug sensitve) vs isogenic drug resistant-derived subline Two condition experiment: two BRAF-V600E mutant cell lines (drug sensitive - parental baseline) vs two derived sublines after chronic exposure to the MEK inhibitor trametinib (drug resista...
ORGANISM(S): Homo sapiens 
2014-04-21 | E-GEOD-49430 | biostudies-arrayexpress
TranscriptomicsBRAF-induced tumorigenesis is IKKalpha dependent but NF?B independent
Tumor cells carrying KRAS mutations activate the NF-?B pathway by different mechanisms, which contribute to the acquisition of essential cancer properties. The BRAF kinase, a downstream mediator of KRAS, is also mutated in a subset of colorectal cancers (CRC), which predicts bad prognosis and therap...
ORGANISM(S): Homo sapiens 
2015-05-08 | E-GEOD-57979 | biostudies-arrayexpress
ProteomicsRICTOR/mTORC2 downregulation in BRAF V600E melanoma cells promotes resistance to BRAF/MEK inhibition
Background Main drawback of BRAF/MEK inhibitors (BRAF/MEKi)-based targeted therapy in the management of BRAF- mutated cutaneous metastatic melanoma (MM) is the development of therapeutic resistance. We aimed to define in this context the specific role of mTORC2, a signaling complex defined by the pr...
ORGANISM(S): Homo sapiens (Human) 
2024-06-22 | PXD050614 | Pride
Targeted therapy Rictor Braf v600e melanoma Mitochondrial metabolism Drug resistance Nampt Mtorc2 
ProteomicsRictor/mTORC2 downregulation in BRAFV600E melanoma cells promotes resistance to BRAF/MEK inhibition
Nearly 50% of cutaneous melanomas carry activating mutations on the BRAF oncogene, and the combination of BRAF- and MEK-inhibitors (BRAF/MEKi) is frequently used for their clinical management. One major drawback of BRAF/MEKi targeted therapy is the rapid development of therapeutic resistance, which ...
ORGANISM(S): Homo sapiens (Human) 
2024-05-23 | PXD045346 | Pride
Brafv600e Mtorc2 Braf Rictor Melanoma 
ProteomicsMolecular Glue Degraders of HuR to Treat BRAF-Mutant Colorectal Cancer
BRAF gain-of-function mutations, particularly BRAF(V600E), affect roughly 10% of all colorectal cancer (CRC) patients, and portend poor prognosis with limited therapeutic interventions. BRAF inhibitors such as Encorafenib are ineffective due to MAP kinase pathway reactivation driven by BRAF dimeriza...
ORGANISM(S): Homo Sapiens 
2026-04-19 | PXD077365 |
TranscriptomicsExpression profiling of BRAFV600E melanoma cell lines upon RAF inhibition
Microarray expression analysis to identify global changes in transcription in response to RAF inhibition. Genes under RAF control were identified in a panel of BRAFV600E tumor cells, following the short-term inhibition of RAF using a pan-RAF kinase inhibitor, PLX4032 (Plexxikon). For comparison with...
ORGANISM(S): Homo sapiens 
2010-07-18 | E-GEOD-20051 | biostudies-arrayexpress
TranscriptomicsPredominance of MAPK reactivation in early resistance to debrafenib/trametinib combination therapy of BRAF mutant metastatic melanoma.
One third of BRAF-mutant metastatic melanoma patients treated with combined BRAF and MEK inhibition progress within six months. Treatment options for these patients remain limited. Here we analyse twenty BRAFV600 mutant melanoma metastases derived from 10 patients treated with the combination of deb...
ORGANISM(S): Homo sapiens 
2014-12-03 | E-GEOD-61992 | biostudies-arrayexpress
Sort   by:  
 Page size